Aoife Brennan - 27 Jun 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: President and CEO, Director
Issuer ticker: CLYM
Reported as of: 27 Jun 2026
Net transaction value: -$406,979
SEC form: 4
Accepted by SEC: 30 Jun 2026, 19:50:38 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Chandra Adams, as Attorney-in-Fact

Key filing fact

Aoife Brennan filed Form 4 for Climb Bio, Inc. (CLYM) on 30 Jun 2026.

Key facts

This page summarizes Aoife Brennan's Form 4 filing for Climb Bio, Inc. (CLYM).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Jun 2026, 19:50.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: -$406,979.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001714563 Primary reporting owner

Brennan Aoife

Relationship: President and CEO, Director
Address: C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS
Signature: /s/ Chandra Adams, as Attorney-in-Fact
Signature date: 30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLYM transaction

Common Stock

Options Exercise

Transaction value
Shares: +68,750
Change %: +138%
Price
Shares after: 118,633
Date: 27 Jun 2026
Ownership: Direct
Footnotes: F1, F2

CLYM transaction

Common Stock

Sale

Transaction value: $406,979
Shares: -30,902
Change %: -26%
Price: $13.17
Shares after: 87,731
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -68,750
Change %: -33%
Price: $0.000000^*
Shares after: 137,500
Date: 27 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,750
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock

Footnote F2

Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.

Footnote F3

The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Footnote F5

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F6

The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.